Introduction {#Sec1}
============

Acromioclavicular (AC) joint (ACJ) dislocation is a common injury in active young adults \[[@CR5]\]. The prevalence was approximately 9% of shoulder girdle injuries \[[@CR3], [@CR28]\]. AC dislocation is associated with AC and coracoclavicular (CC) ligaments injuries \[[@CR37]\]; such injuries are classified into type I--VI on the basis of the radiographic findings using the Rockwood criteria \[[@CR26], [@CR37]\]. Non-operative treatment has generally been accepted as the gold standard of treatment in Rockwood I and II lesions \[[@CR52]\], whereas the optimal method of treatment for grade III--VI lesions remains a matter of controversy \[[@CR16], [@CR30], [@CR59]\]. Although type IV--VI injuries are treated operatively because of their severe instability \[[@CR45]\], treatment for type III injury is still controversial \[[@CR22], [@CR52]\]. The aim of any surgical approach addressing the instability of the ACJ should be an anatomic reduction and restoration of normal arthrokinetics \[[@CR18]\]. Surgical methods employed for the treatment of AC dislocations include extraarticular fixation by CC restoration with metallic cables, autologous ligaments or LARS artificial ligaments, transarticular fixation by hook plate (HP) and Kirschner wires. Kirschner wires and threaded pins are frequently used for temporary fixation of the ACJ. However, serious concerns still exist regarding pin migration or breakage, pin-site infection, fixation failure, and recurrent instability after pin removal \[[@CR14], [@CR21], [@CR31]\]. Currently, two modern techniques that are widely used include HP fixation \[[@CR2], [@CR7], [@CR10], [@CR29], [@CR35], [@CR59]\] and CC ligament fixation using a suspensory loop device \[tightrope (single or double), endo-button (single or double), synthetic ligament and absorbable polydioxansulfate sling (PDS)\] \[[@CR7], [@CR8], [@CR10], [@CR12], [@CR19], [@CR31], [@CR32], [@CR35], [@CR36], [@CR39], [@CR51]\]. Many case series have reported safe and effective results with the treatment of acute unstable ACJ dislocations by loop suspensory fixation (LSF) \[[@CR1], [@CR8], [@CR9], [@CR12], [@CR20], [@CR24], [@CR40], [@CR42], [@CR43], [@CR50], [@CR55]\] and hook plating \[[@CR7], [@CR17], [@CR25], [@CR38], [@CR39], [@CR49], [@CR56], [@CR57]\]. More recently, several retrospective cohort studies have aimed to investigate the results of treatment for unstable acute AC dislocations (type III--VI) with HP and LSF. However, there has been no consensus as to which is better for treatment of acute unstable ACJ dislocation. Some studies show benefits of the AC or CC augmentations in pain and Constant-Murley score (CMS) \[[@CR29], [@CR59]\], whereas other studies do not \[[@CR2], [@CR10], [@CR18]\]. However, LSF consists of variable types of fixation, which include tightrope (single or double), endo-button (single or double), synthetic ligaments and absorbable PDS. Moreover, no high quality methodological quality study \[prospective cohort or randomized controlled trials (RCT)\] has recently been published. We hypothesized that the impact of each type of fixation with LSF would be comparable to that the HP fixation in acute unstable AC joint dislocation. We therefore conducted a systematic review and meta-analysis that analyzes the available literature, with the aim of comparing the outcomes and safety of LSF, including all different types of implants (tightrope, endo-button, synthetic ligament and PDS) with HP fixation for treatment of acute unstable AC joint dislocation. These clinical outcomes consist of the CMS, Pain Visual Analog score (VAS) and postoperative complications.

Materials and methods {#Sec2}
=====================

Search strategy {#Sec3}
---------------

The Medline and Scopus databases were used for identifying relevant studies published in English since the date of inception to 5 October 2015. The PubMed and Scopus search engines were used to locate studies with the following search terms: {\[(acromioclavicular joint) OR AC joint\] AND \[(separation) OR dislocation OR trauma OR injury\] AND \[(hook plate) OR locking plate OR fixation OR tightrope OR dogbone\] AND \[(Constant score) OR Constant Murley scale OR CMS OR pain OR UCLA\]}. Search strategies for Medline and Scopus are described in detail in the "Appendix 1". References from the reference lists of included trials and previous systematic reviews were also explored.

Inclusion criteria {#Sec4}
------------------

Observational studies (e.g., cross-sectional or cohort) that reported clinical outcomes of hook plate or fixation of the CC ligament using an LSF device for treatment of acute unstable ACJ injury were eligible if they met the following criteria:Reported at least one of the following outcomes: CMS, VAS, and postoperative complications.Had sufficient data to extract and pool, i.e., the reported mean, standard deviation (SD), number of subjects according to treatments for continuous outcomes, and number of patients according to treatment for dichotomous outcomes.

The use of a combination of LSF or HP with other methods of fixation and non-English studies were excluded. The reference lists of the retrieved articles were also reviewed to identify publications on the same topic. Where there were multiple publications from the same study group on the same population, the most complete and recent results were used.

Data extraction {#Sec5}
---------------

Two reviewers (J.K. and A.A.) independently performed data extraction using standardized data extraction forms. General characteristics of the study \[i.e., mean age, gender, body mass index (BMI), mean follow up time, mean duration after injury, pain VAS and CMS score at baseline\] were extracted. The number of subjects, mean, and SD of continuous outcomes (i.e., VAS and CMS) between groups were extracted. Cross-tabulated frequencies between treatment and all dichotomous outcomes (post-operative complications) were also extracted. Any disagreements were resolved by discussion and consensus with a third party (M.B.).

Outcomes of interest {#Sec6}
--------------------

The outcomes of interests included CMS, VAS, and postoperative complications. These outcomes were measured as reported in the original studies, which were VAS pain scale from 0 to 10 cm (lower values of these scores refer to better outcomes), CMS (0--100, higher values are equivalent to better outcomes). Postoperative complications (wound problems, loss of reduction, implant migration and osteolysis) were considered.

Statistical analysis {#Sec7}
--------------------

For continuous outcomes (CMS and VAS), unstandardized mean differences (UMD) was pooled and calculated using the method as follows \[[@CR53]\]: UMD $\documentclass[12pt]{minimal}
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For dichotomous outcomes (complications), the prevalence was pooled and calculated using the inverse variance method as follows \[[@CR53]\] $\documentclass[12pt]{minimal}
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Meta-regression analysis was then applied to explore causes of heterogeneity \[[@CR15], [@CR54]\]. Coverable parameters, i.e., type of implants (single and double loops), mean age, percentage male, and type of injuries (III, IV, V and VI) were considered in the meta-regression model. Power of the test for meta-regression was also assessed \[[@CR44]\]. The UMD and odds ratio (OR) were estimated by indirect meta-analysis using a random effects model, otherwise a fixed effects model was applied. All analyses were performed using STATA version 14.0 \[[@CR48]\].

Results {#Sec8}
=======

In all, 231 and 387 studies were identified from Medline and Scopus respectively, as described in Fig. [1](#Fig1){ref-type="fig"}, of which 49 studies were duplicates, leaving 569 studies for review of titles and abstracts. Of these, 36 articles were relevant and the full papers were retrieved. Characteristics of these studies are described in Table [1](#Tab1){ref-type="table"}: 28 studies were case series reports, 7 were cohort studies and 1 study was a cross-sectional study. Twenty studies reported results of LSF, 11 studies reported results of HP fixation, and 5 studies compared LSF to HP fixation. All 36 studies reported postoperative complications, 25 studies for LSF (22 studies were reported CMS and 12 studies were VAS for pain), and 16 studies for HP fixation (13 studies were reported CMS and 10 studies were VAS for pain). Mean age, percentages of male gender, duration from injury and mean follow up of LSF participants varied from 26 years to 45.6 years, 72.7% to 94.4%, 4.2 days to 13 days and 3 months to 70 months, while HP varied from 29 years to 42.3 years, 84.4% to 100%, 3.5 days to 9.2 days and 3 months to 50.4 months. In all 36 studies, fixation was performed in ACJ injury types III--VI. Twenty-two studies were type III and V, 6 studies were type III, 6 studies were type V, 1 study was type III--IV, 1 study was type IV--V and 1 study was type IV--VI. In the LSF group, 13/24 studies used arthroscopically assisted techniques, as did 4/16 studies in the hook plate group; 12/25 studies used double loop and 13/25 studies used single loop fixation. In the HP group, 14/16 studies reported the time of plate removal, with 8 studies removing the plates within 3 months of initial operation, 4 studies removing the plates at 4 months, and 2 studies removing the plates after 4 months.Fig. 1Flow of study selection Table 1Characteristics of included studiesAuthorYearType of studyFollow up (months)Arthroscopic assistedSuspensory loop (single or double) or HPImplant typesImplant removal time (month)AgeType of AC injuryMale (%)Time interval from injury to surgery (days)OutcomeStam L1991Case series46.8NSingleDacron--40III--V73.94.4ComplicationsDimakopoulos P2006Case series33.2NDoubleEthibond--33.5III/V91.210CMS, complicationsRyhanen J2006Case series12NSingleC-hook337III----ComplicationsChoi S2008Case series41.2NSingleEthibond--33.5III--V80--VAS, complicationsMurena L2009Case series31NDoubleEndobutton--33.3III--V93.84.3CMS, complicationsGreiner S2009Case series70NSinglePDS--35.3III--V86--CMS, complicationsSalzmann GM2010Case series24YDoubleTightrope--37.5III--V91.311.3CMS, VAS, complicationsScheibel M2011Case series26.5YDoubleTightrope--38.6III/V92.97.3CMS, complicationsWai HF2011Case series12NDoubleEndobutton--42.8III--V86.76.5CMS, VAS, complicationsEl Sallakh SA2012Case series24YSingleTightrope--30V90--CMS, complicationsSandmann GH2012Case series32NDoubleTightrope--39III--V915CMS, VAS, complicationsBeris A2013Case series18.25NSingleTightrope--27.5III--IV755CMS, VAS, complicationsKraus N2013Cohort24NDouble (V)Tightrope--37.7V93.3--CMS, complicationsKraus N2013Cohort24NDoubleTightrope--40.9V92.3--CMS, complicationsVenjakob AJ2013Case series58YDoubleTightrope----III--V91.3--CMS, VAS, complicationsSpolitil M2014Case series5YSingleTightrope--33III--V84.2--CMS, VAS, complicationsAcar MA2015Case series13.6YSingleZiploop--43.4III92.37.92CMS, VAS, complicationsKatsenis DL2015Case series42NSingleFlipptack--35.5IV--V764.2CMS, complicationsPan Z2015Case series24YSingleEndobutton--26III/V72.76.1CMS, complicationsShin SJ2015Case series25.6YSingleTightrope--45.4III--V94.46.1CMS, complicationsStruhl S2015Case series62.4YSingleEndobutton--45.7III--V88.913CMS, complicationsKoukakis A2008Case series10.6NHPHP2--3--III--V--7.3CMS, VAS, complicationsSalem KH2009Case series30NHPHP2.541III--V927CMS, complicationsKienast B2011Case series36NHPHP338.4III--V83.76ComplicationsFrancesco AD2012Case series12NHPHP327.5III/V66.73.5CMS, complicationsGille J2013Case series7YHPHP----III/V----CMS, complicationsSarrafan N2012Case series12NHPHP838III90--VAS, complicationsGuizzi P2012Case series21NHPHP----III----CMS, complicationsHeideken JV2013Case control32NHPHP440V77.30.3CMS, VAS, complicationsJafary D2014Case series19NHPHP540.3III/V91.7--CMS, complicationsSteinbacher G2014Case series50.4NHPHP429III73.7--VAS, complicationsKumar N2015Case series23.5NHPHP434.24III1009.06CMS, complicationsEscher A2011Cohort31.2NSingle vs HPPDS442.3V88.58.5VAS, CMS, complicationsAndreani L2014Cohort3NSingle vs HPTightrope3--IV--VI1007.2CMS, complicationsJensen G2014Cohort48YDouble vs HPTightrope339III/V91.1--VAS, CMS, complicationsMetzlaff S2016Cohort32YSingle vs HPFlippTack337.6III/V79.514CMS, complicationsYoon JP2015Cohort--YDouble vs HPLIGASTIC240V78.69.2VAS, CMS, complications*HP* Hook plate,*AC* acromioclavicular, *PDS* polydioxansulfate sling, *CMS* Constant-Murley score, *VAS* Visual Analog score

Pooled mean CMS in LSF and HP {#Sec9}
-----------------------------

Thirty-eight studies using LSF and HP fixation in high-grade acute ACJ injury were included for pooling of means and 95% confidence intervals (CI) (Table [2](#Tab2){ref-type="table"}). Among 23 LSF studies, 15 were single bundle fixation, 10 were double bundle fixation, 12 were arthroscopically assisted and 13 were open technique. In terms of CMS, with the LSF group containing 663 patients and HP fixation having 394 patients, the pooled mean CMS of LSF varied greatly across studies (*I* ~2~ = 75.2) and was 92.48 (95% CI 90.91, 94.05) (Table [2](#Tab2){ref-type="table"}). The pooled mean of CMS of 16 HP studies varied across studies (*I* ~2~ = 85.47) at 90.35 (95% CI 87.16, 93.54). From the result of the indirect meta-analysis, the pooled UMD were 2.13 (95% CI −1.43, 5.69), which translates to the mean CMS of LSF scoring 2.13 higher than HP fixation but the difference was not statistically significant.Table 2Estimation of the pooled mean of CMS and VAS pain of loop suspensory fixation (LSF) and HPAuthorFollow up (months)Age (years)Male (%)*N*CMSVASMeanSDMeanSDDimakopoulos P33.233.591.21593.58.05----Choi S41.233.5802689.58.13----Murena L3133.393.816975.48----Greiner S7035.3865091.78.7----Salzmann GM2437.591.32394.33.20.250.5Scheibel M26.538.692.93791.757.51----Wai HF1242.886.71589.157.610.20.62El Sallakh SA2430901096.41.44----Sandmann GH3239913394.37.10.50.6Beris A18.2527.5751294.76.30.170.58Kranus N2437.793.31588.51.85----Kranus N2440.992.31392.24.62----Venjakob AJ58--91.32391.54.70.320.6Spolitil M53384.21989.710.92.111.76Acar MA13.643.492.31384.465.50.691.3Katsenis DL4235.5765093.024.63----Pan Z242672.72292.512.4----Shin SJ25.645.494.418972.19----Struhl S62.445.788.9998.81.1----Escher A31.242.388.55294.610.80.2Andreani L3--10028907.5----Jensen G483991.15682.514.361.31.7Metzlaff S3237.679.54493.63.4----Yoon JP--4078.64289.23.51.31.3Pooled mean LSF (95% CI)92.48 (90.91, 94.05)0.32 (0, 0.64)Koukakis A10.6----1696.46.70.871.76Salem KH30419223971.94----Francesco AD1227.566.74291.799.2----Sarrafan N12389030----41.73Escher A31.242.388.55291.22.20.770.2Guizzi P21----1293.236.47----Gille J7----390.755.2----Heideken JV324077.319901.762.51.76Andreani L3--10028755.8----Jensen G483991.15673.824.241.72.3Metzlaff S3237.679.54492.83.8----Steinbacher G50.42973.719----1.80.58Jafary D1940.391.72494.58.77----Kumar N23.534.241003391.813.07----Yoon JP--4078.64290.29.91.61.5Pooled mean HP (95% CI)90.35 (87.16, 93.54)1.51 (0.73, 2.00)UMD (95% CI) of LSF vs hook plate2.13 (−1.43, 5.69)−1.19 (−2.03, −0.35)*UMD* Unstandardized mean differences

Pooled mean VAS in LSF and HP {#Sec10}
-----------------------------

Ten LSF studies and seven hook plate studies were pooled for VAS pain scores. For the LSF group of 288 patients and HP group of 234 patients, the pooled mean VAS of LSF and HP were homogenous across studies (*I* ^2^ = 0 and 15.09), scoring 0.32 (95% CI 0, 0.64) and 1.51 (95% CI 0.73, 2) (Table [2](#Tab2){ref-type="table"}). From indirect meta-analysis, the pooled UMD were −1.19 (95% CI −2.03, −0.35), translating to the mean VAS of LSF being about 1.2 scores statistically significantly lower when compared to hook plating.

Pooled prevalence of LSF and HP {#Sec11}
-------------------------------

Twenty-five LSF studies and 16 hook plate studies pooled the prevalence of complications after fixation. For the LSF group of 701 patients and HP group of 668 patients, the pooled prevalence of LSF and HP had mild to moderate degrees of heterogeneity across studies (*I* ^2^ = 24.27 and 42.13), with scores of 0.08 (95% CI 0.06, 0.10) and 0.05 (95% CI 0.02, 0.08) (Table [3](#Tab3){ref-type="table"}). From indirect meta-analysis, the difference in the risk of having complications between two groups was 1.69 (95% CI 1.07, 2.60), indicating that the chance of having a wound problems, loss of reduction, implant migration and osteolysis in the LSF group was about 1.7 times statistically significant higher than in the HP group (Table [3](#Tab3){ref-type="table"}).Table 3Estimation of the pooled prevalence of post-operative complication of LSF and HPAuthorFollow up (months)Age (years)Male (%)*N*ComplicationYesNoStam L46.84073.923023Dimakopoulos P33.233.591.215232Ryhanen J1237--15114Choi S41.233.58026119Murena L3133.393.816214Greiner S7035.38650446Salzmann GM2437.591.323122Scheibel M26.538.692.937040Wai HF1242.886.715213El Sallakh SA24309010010Sandmann GH32399133330Beris A18.2527.57512012Kranus N2437.793.315013Kranus N2440.992.313114Venjakob AJ58--91.323221Spolitil M53384.219316Acar MA13.643.492.313112Katsenis DL4235.57650650Pan Z242672.722220Shin SJ25.645.494.418810Struhl S62.445.788.9945Escher A31.242.388.552025Andreani L3--10028217Jensen G483991.1561214Metzlaff S3237.679.544123Yoon JP--4078.642612Pooled prevalence LSF (95% CI)0.08 (0.06, 0.10)Koukakis A10.6----16016Salem KH30419223716Kienast B3638.4--22524201Francesco AD1227.566.742537Sarrafan N12389030129Escher A31.242.388.552522Guizzi P21----1211Gille J7----303Heideken JV324077.319019Andreani L3--1002807Jensen G483991.1561911Metzlaff S3237.679.544020Steinbacher G50.42973.719019Jafary D1940.391.724222Kumar N23.534.2410033033Yoon JP--4078.642915Pooled prevalence HP (95% CI)0.05 (0.02, 0.08)RR of LSF vs HP 1.69 (1.07, 2.60)

Sources of heterogeneity {#Sec12}
------------------------

Meta-regression was applied to explore the cause of heterogeneity by fitting a co-variable (i.e., age, percentage of sex, type of AC injury, approach, number of bundle, time of plate removal, duration before surgery and type of studies level), and meta-regression was applied to assess this. None of the co-variables could explain the heterogeneity. However, the type of approaches and number of bundles of fixation might be the source of heterogeneity. Therefore, subgroup analyses were performed as described in Table [4](#Tab4){ref-type="table"}.Table 4Estimation of the pooled mean CMS, VAS, and prevalence of complications in the LSF subgroupSubgroup analysisMean95% CI*Q* test*dfI* ~2~*P* valueCMS Pooled mean CMS of arthroscopic assisted LSF92.4190.68, 94.1321.641049.170.027 Pooled mean CMS of open LSF92.4089.89, 94.9265.451183.19\<0.001 Arthroscope versus open LSF0.01 (−3.04, 3.06) Pooled mean CMS of single bundle LSF93.3191.30, 95.3251.321276.62\<0.001 Pooled mean CMS of double bundle LSF91.4889.49, 93.4822.321055.190.016 Single versus double LSF1.83 (−1.22, 4.88) Pooled mean CMS of HP within 3 months88.4282.75, 94.10407.28698.53\<0.001 Pooled mean CMS of hook plate after 3 months91.0889.85, 92.3210.08370.230.018 Plate remove within versus after 3 months−2.66 (−14.05, 8.73) Pooled mean CMS of HP open90.0886.66, 93.5082.021186.59\<0.001VAS Pooled mean VAS of arthroscopic assisted LSF1.140.07, 1.492.25500.813 Pooled mean VAS of open LSF0.660.08, 1.160.76300.858 Arthroscope versus open0.48 (−0.48, 1.44) Pooled mean VAS of single bundle LSF1.130.06, 1.441.65300.649 Pooled mean VAS of double bundle LSF0.410.21, 1,.151.17500.948 Single versus double0.72 (−0.69, 2.13) Pooled mean VAS of HP within 3 months1.501.19, 1.862.65224.370.267 Pooled mean VAS of HP after 3 months2.231.11, 3.35175.40398.3\<0.001 Plate remove within versus after 3 months−0.73 (−3.06, 1.60) Pooled mean VAS of HP open1.510.75, 2.277.07615.090.315ComplicationsPrevalence95% CI*Q* test*dfI* ~2~*P* valuePooled prevalence of arthroscopic assisted LSF0.10.04, 0.1529.991163.320.002Pooled prevalence of open LSF0.080.05, 0.113.021300.998Arthroscope versus open LSF1.31 (0.77, 2.23)Pooled prevalence of single bundle LSF0.070.04, 0.0922.821438.650.063Pooled prevalence of double bundle LSF0.10.06, 0.138.331000.597Single versus double0.67 (0.38, 1.15)

Discussion {#Sec13}
==========

From the current available evidence, this systematic review and meta-analysis has shown the following: LSF implants have higher shoulder function and lower shoulder pain reported by CMS and VAS scores of 2.2 and 1.2 points, respectively, when compared to HP fixation. However, LSF displayed a higher complication rate after surgery, (wound problems, loss of reduction, implant migration and osteolysis) being 1.7 times higher than HP fixation in acute unstable ACJ injury.

Of the previously published studies \[[@CR2], [@CR10], [@CR18], [@CR29], [@CR59]\], there have been no high quality studies comparing the results of these two fixation methods. Although there are comparative studies reporting results between the two groups, there is still no clear consensus as to which is preferable. From this study, we have additional evidence that LSF displays a higher improvement of CMS and VAS scores when compared to HP fixation. However, LSF has a higher risk of postoperative complications when compared to HP fixation. The mean CMS, VAS Pain score and prevalence of complications among included studies was heterogeneous, possibly due to methodological and clinical differences. Attempts were made to explore sources of heterogeneity by considering clinical (i.e., age, percentage of sex, type of AC injury, approach, number of bundle, time of plate removal and duration before surgery) and methodological variables (i.e., type of study) in the meta-regression model. None of the co-variables could explain the heterogeneity. However, the degree of heterogeneity did not decrease after pooling all subgroups, indicating the presence of other sources of heterogeneity. There are several important clinical factors that may have had an effect on the results, including the use of two different approaches (arthroscopic or open) and two different implant designs (single or double) that are suspected to be the source of heterogeneity of the LSF devices. Although LSF shows higher complication rates postoperatively, HP fixation is a double procedure that also requires a second surgery for plate removal. After subgroup analyses, the results show that there are still no statistically significant differences in CMS, VAS and complications between different approaches and the number of bundle fixation (Table [4](#Tab4){ref-type="table"}). The timing of the second operation for plate removal displays no statistically significant difference for CMS and VAS outcomes comparing before 3 months and after 3 months of the initial surgery.

Although we were unable to find the source of heterogeneity by meta-regression and subgroup analysis (two different approaches, two different implant designs of LSF devices and the plate removal time after hook plating), several factors must be considered in clinical implementation. Firstly, there is either single \[[@CR1], [@CR2], [@CR4], [@CR6], [@CR9], [@CR10], [@CR12], [@CR20], [@CR29], [@CR34], [@CR38], [@CR43], [@CR46], [@CR47], [@CR50]\] or double (V anatomic shape \[[@CR24]\] with parallel \[[@CR8], [@CR18], [@CR33], [@CR40], [@CR42], [@CR55], [@CR58], [@CR59]\]) bundle LSF fixation, in which double bundles demonstrate higher function scores (CMS) and lower pain VAS. Within the double bundle groups, no significant differences regarding clinical or radiologic results have been found \[[@CR24]\]. Secondly, arthroscopic techniques have recently been described in the treatment of acute AC dislocation \[[@CR1], [@CR9], [@CR18], [@CR29], [@CR34], [@CR40], [@CR42], [@CR43], [@CR46], [@CR50], [@CR55], [@CR59]\]. With the use of an arthroscopic approach, LSF seems to have higher pain VAS when compared to open LSF \[[@CR2], [@CR4], [@CR6], [@CR8], [@CR10], [@CR12], [@CR20], [@CR24], [@CR33], [@CR38], [@CR47], [@CR58]\], but shows no differences in terms of function, outcomes or complication rates. For HP fixation, most studies used an open approach \[[@CR7], [@CR13], [@CR17], [@CR21], [@CR23], [@CR39], [@CR41], [@CR49], [@CR56]\], with only one study using an arthroscopic approach \[[@CR11]\]. However, after subgroup analysis, there were no differences in pain function and complication outcomes. As for the time of implant removal after initial surgery in the hook plating group, pain VAS was lower when the plate was removed within 3 months \[[@CR2], [@CR7], [@CR18], [@CR21], [@CR23], [@CR29], [@CR39], [@CR59]\], while the CMS function score was higher when the plate was removed after 3 months \[[@CR10], [@CR17], [@CR25], [@CR41], [@CR49], [@CR56]\] (Table [4](#Tab4){ref-type="table"}). Therefore, the recommended time to remove the implant will depend on the symptoms of each individual patient. If there is persistent pain after surgery, the HP should be removed before 3 months. If the patient has no pain but limited shoulder function; the implant should not be removed prior to 3 months postoperatively.

The strength of this study is that it has a high power to detect a clinical difference between two implant fixations (the minimal clinically important difference of VAS is 1.2 points), with a power of 100% to detect this margin, and a type I error of 1%. This study uses adequate methodology of systematic review in accordance with*Preferred Reporting Items for Systematic Reviews and Meta-Analyses* (PRISMA) guidelines \[[@CR27]\], as well as providing exploration and reduction of the heterogeneity of the studies using subgroup analysis and adequate statistical analysis.

There were some limitations in this study. Firstly, the quality of studies for the meta-analysis was not high. Ideal evidence for systematic review is an RCT, which is most commonly used in testing the efficacy of surgery. Only 5 trials included were comparative studies (retrospective cohort studies) while 31 trials included were case series reports. This could be a possible source of bias between groups due to the opportunity for selection and different baseline characteristics. Secondly, heterogeneity remains an important factor to be considered in the conduct and interpretation of meta-analysis, and the heterogeneity between studies was great. We applied the random effects meta-analysis to adjust for the differences between studies, and the possible causes of heterogeneity were explored if covariate data at baseline (e.g., age, percentage of sex, type of AC injury, approach, number of bundle, timing of plate removal, duration before surgery and type of studies) were available. The third limitation is that indirect meta-analysis was used for calculating the mean difference and odds ratio between the two groups, due to the fact that most included studies were case series reports of only one technique. The fourth limitation is that there are other outcomes of interest that can be used to compare LSF and HP fixation such as operation cost or post-operative satisfaction and quality of life. However, these factors could not be analyzed because of insufficient data. The last limitation is that most studies had a mean follow up time of approximately 1--2 years; therefore mid-term to long-term effects of the different types of fixation are still unknown.

In summary, for acute high-grade ACJ injuries, both HP and LSF had acceptable post-operative outcomes. LSF provided better postoperative shoulder function (CMS) when compared to HP fixation, but the difference was not statistically significant. LSF provided clinically and statistically significant lower pain VAS when compared to HP fixation. However, LSF had higher complication rates when compared to the HP fixation group. This study shows that both options have advantages and disadvantages and should be chosen based on patient status. In the future, prospective randomized controlled studies are needed to confirm these findings as the current literature is still insufficient.

Appendix {#Sec14}
========

Search term and strategy {#Sec15}
------------------------

\#1 acromioclavicular joint

\#2 AC joint

\#3 \#1 OR \#2

\#4 separation

\#5 dislocation

\#6 trauma

\#7 injury

\#8 \#4 OR \#5 OR \#6 OR \#7

\#9 hook plate

\#10 locking plate

\#11 fixation

\#12 tightrope

\#13 dogbone

\#14 \#9 OR \#10 OR \#11 OR \#12 OR \#13

\#15 Constant score

\#16 Constant Murley scale

\#17 CMS

\#18 pain

\#19 UCLA

\#20 \#15 OR \#16 OR \#17 OR \#18 OR \#19

\#21 \#3 AND \#8 AND \#14 AND \#20
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